However, our data study mirrors the real-world application situation of PD-1/PD-L1 inhibitor therapy in NSCLC patients in standard clinical practice and is the first of its kind showing a positive survival association between combinatory PD-1/PD-L1 inhibitor and VA therapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.